Research Desk Line-up: Radius Health Post Earnings Coverage
Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for OncoSec Medical Inc. (NASDAQ: ONCS) (“OncoSec”), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=ONCS. The biotechnology Company, which has developed DNA-based intratumoral immunotherapies using the investigational technology ImmunoPulse® for the treatment of cancer, announced on November 08, 2017, positive updated long-term follow-up data from its Phase-2 OMS I-102 combination study of ImmunoPulse IL-12 and pembrolizumab in patients unlikely to respond to anti-PD-1 therapy. For immediate access to our complimentary reports, including today’s coverage, register for free now at:
Discover more of our free reports coverage from other companies within the Biotechnology industry. Pro-TD has currently selected Radius Health, Inc. (NASDAQ: RDUS) for due-diligence and potential coverage as the Company reported on November 02, 2017, its financial results for Q3 2017 which ended on September 30, 2017 and also provided a business update. Tune in to our site to register for a free membership, and be among the early birds that get our report on Radius Health when we publish it.
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on ONCS; also brushing on RDUS. Go directly to your stock of interest and access today’s free coverage at:
Dr. Alain Algazi will present the updated data in an oral poster presentation (P524) at the Society for Immunotherapy of Cancer (SITC) Annual Meeting to be held in National Harbor, Maryland on November 10th, 2017 at 12:45 p.m. EST.
- The ImmunoPulse technology has been specifically designed to improve the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12 (tavokinogene telseplasmid or tavo).
- OncoSec’s lead program, ImmunoPulse® IL-12 has exhibited a favorable safety profile in its Phase-1 and Phase-2 clinical trials. It has confirmed the evidence of anti-tumor activity in the treatment of various solid tumors and has also shown the potential to reach beyond the site of local treatment to initiate a systemic immune response.
- As present, it is in the clinical development for metastatic melanoma and triple-negative breast cancer. Basically, it is focusing on patients with melanoma who are refractory or have relapsed on anti-PD-1 therapies.
About the Phase-2 Trial
- PISCES/KEYNOTE-695 is the global, multicenter phase-2b, open-label trial for intratumoral plasma encoded IL-12, which is being delivered by electroporation in combination with intravenous pembrolizumab in patients with stage III/IV melanoma who have progressed or are progressing on either pembrolizumab or nivolumab treatment.
- The Simon 2-stage study of intratumoral tavo plus electroporation in combination with pembrolizumab has enrolled nearly 48 patients with histological diagnosis of melanoma with progressive locally advanced or metastatic disease defined as Stage III or Stage IV. The primary endpoint is the Best Overall Response Rate (BORR).
Updated Data Validates the Combination of ImmunoPulse With Pembrolizumab
- The updated clinical and correlative immune-focused biomarker data from Phase-2 trials shows a progression free survival (PFS) rate of 57% at 15 months with 100% duration of response and median PFS not yet reached.
- The updated data builds upon the formerly reported data of a best overall response rate of 50% (which is 41% complete response rate). This proves that the combination of ImmunoPulse IL-12 with Pembrolizumab can lead to a coordinated innate and adaptive immune response. This also validates a synergistic relationship with anti-PD-1.
- Moreover, these findings suggest that this combination can lead to a paradigm shift in the tumor microenvironment. This combination yields a strong intratumoral and systemic anti-tumor response by converting cold tumors to hot and possibly improving clinical outcomes for patients who do not respond to anti-PD-1 therapy.
Comments from the Industry
Dr. Alain Algazi, Lead Trial Investigator, Associate Professor, Department of Medicine (Hematology/Oncology) at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center stated that the Phase-2 trial results are mostly positive including progression free survival beyond two years in multiple patients, duration of response, best overall response rate, and tolerability of the combination.
Overall, these suggest a strong and consistent result across multiple endpoints, emphasizing that the combination of ImmunoPulse IL-12 with pembrolizumab makes for a viable treatment option for patients diagnosed with metastatic melanoma.
Likewise, Dan O’Connor, CEO of OncoSec, mentioned that the strong PFS benefit and tolerability noted with the combination of ImmunoPulse IL-12 and pembrolizumab is the first demonstrating efficacy in a predicted PD-1 non-responder population. This signifies that this combination is an important addition to the current treatment landscape for metastatic melanoma patients who have progressed or are progressing on anti-PD-1 therapy.
Last Close Stock Review
On Thursday, November 09, 2017, the stock closed the trading session at $2.09, rising 4.50% from its previous closing price of $2.00. A total volume of 7.78 million shares have exchanged hands, which was higher than the 3-month average volume of 1.64 million shares. OncoSec Medical’s stock price skyrocketed 117.71% in the last three months, 86.61% in the past six months, and 26.67% in the previous twelve months. Furthermore, since the start of the year, shares of the Company have soared 69.92%. At Thursday’s closing price, the stock’s net capitalization stands at $59.52 million.
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.